Patent · US Active

Tau immunotherapy

US11492393B2 · kind B2 · utility

1Cited by
21References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 20, 2020
Grant dateNov 8, 2022
Priority date—
Expiry dateJul 21, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.